Annexon, Inc. (ANNX) research
Annexon, Inc.- Sector
- Biotechnology
- Last price
- $4.20
- As of
Kresmion compiles this page from ANNX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Annexon, Inc. (ANNX): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-12.
As of . Source: SEC EDGAR filings for ANNX. Method and limitations.
Share the ANNX intelligence card
See the full ANNX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ANNX on one page. Preview it with sample data, then open it live with a free account.
Preview the ANNX dossierActive signals for ANNX
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 14.8%, EPS $-0.28 vs $-0.2438 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +153% to ANNX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +567% to ANNX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1595% to ANNX (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 62% of ANNX (2026Q2)
FREE, NO ACCOUNT
Every signal on ANNX, as it fires
You are seeing 5 of 8 signals recorded on ANNX since 2026-07-24.
The five above landed across 2 days. The other 3 were recorded on 2 other days. 6 of the 8 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ANNX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 03589W102 · 2026Q2 | $7.9M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 03589W102 · 2026Q2 | $6.8M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 03589W102 · 2026Q2 | $3.4M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 03589W102 · 2026Q2 | $2.9M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 03589W102 · 2026Q2 | $2.6M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 03589W102 · 2026Q2 | $1.5M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ANNX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
ANNX against its peers
ANNX's return on equity of -97.7% ranks in the 18th percentile of 19 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | ANNX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 42.7M | n/a | 11 |
| Operating margin | n/a | -229.1% | n/a | 10 |
| Net margin | n/a | -237.9% | n/a | 11 |
| Return on equity | -97.7% | -42.8% | 18 | 19 |
Peers (20): ACHV, AVTX, LXRX, DSGN, GERN, FDMT, SGP, OLMA, SLDB, CADL, GYRE, DBVT, IMMX, SANA, WVE, IMMP, ABUS, VSTM, ARDX, TBPH. Left out: ATTO (no annual filing), OBX (no annual filing), HELP (period gap), ETRA (no annual filing), IVA (period gap). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ANNX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ANNX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ANNX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.